Sweden · Delayed Price · Currency is SEK Cinclus Pharma Holding AB Earnings Call Transcripts
Fiscal Year 2025
-
Linaprazan glurate advances through phase III with strong financial backing and global partnerships, targeting blockbuster potential in severe erosive GERD. Revenue growth is driven by licensing deals, while regulatory and clinical milestones position the product for 2026 launches.
-
Linaprazan glurate is poised to address major unmet needs in severe erosive GERD, offering best-in-class acid control and rapid symptom relief. The large, dynamic market supports strong commercial potential, but success will require focused marketing and differentiation among specialists.
-
Phase III trial for linaprazan glurate is underway with strong recruitment and positive regulatory feedback. Financials show increased R&D investment and a solid cash runway into 2027, while global PCAB market momentum supports future commercial prospects.
-
Linaprazan glurate, a next-generation PCAB, is in Phase III trials targeting severe GERD patients with unmet needs, aiming for premium pricing and specialist market focus. Strong IP, a major European partnership, and a U.S. launch planned for 2029-2030 underpin the strategy.
-
Secured a EUR 220 million Zentiva partnership for Linaprazan glurate in Europe, with phase III trial preparations complete and imminent start. Cash position remains strong at SEK 589 million, and U.S. commercialization rights are retained for future value creation.
-
A strategic partnership with Zentiva secures up to EUR 220 million for linaprazan glurate's European commercialization, with strong royalty terms and a 10-year exclusivity. Zentiva's pan-European reach and specialty pharma focus support targeting severe GERD patients and may accelerate clinical development.
-
Lead asset linaprazan glurate advances to Phase III after strong Phase II results, targeting severe eGERD with best-in-class potential and robust patent protection. Cash reserves support operations through 2026, with premium pricing and dynamic market opportunities anticipated.
Fiscal Year 2024
-
PCABs are rapidly gaining market share globally, with linaprazan glurate now approved in China and pivotal Phase III trials set for the U.S. and Europe. Financials remain strong after a major share issue, supporting operations through key 2026 milestones.
-
Development of linaprazan glarate advances with phase III trial preparations on schedule and strong IP protection extending beyond 2040. Cash reserves remain robust post-IPO, with further financing planned after key clinical milestones.
-
Strong cash position after a SEK 750 million IPO supports phase III development of a next-gen P-CAB for severe eGERD, with first patient expected in 2025 and key readouts in 2026. Patent protection extends to 2042, and China approval could bring milestone payments by year-end.